NCT04605666View on ClinicalTrials.gov

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions
B Cell LeukemiaB Cell Lymphoma
Interventions
BIOLOGICAL

CD19-CAR-T2 Cells

CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.

Trial Locations (1)

510515

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT04605666 - CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies | Biotech Hunter | Biotech Hunter